You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lenalidomide

Showing 26 - 50 of 662
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
  • +2 more
Oct 18, 2022

Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)

Recruiting
  • Diffuse Large-cell B-cell Lymphoma
  • plamotamab
  • +2 more
  • Seattle, Washington
    Swedish Cancer Center
May 2, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome
  • +2 more
  • Wuhan, Hubei, China
    Department of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,

Active, not recruiting
Has Results
  • Plasma Cell Myeloma
  • Transplant-Related Carcinoma
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center
Jul 12, 2022

Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)

Recruiting
  • Mantle Cell Lymphoma
  • MCL
  • Basking Ridge, New Jersey
  • +6 more
Mar 27, 2023

Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Guangzhou, Guangdong, China
  • +10 more
Oct 8, 2023

Multiple Myeloma Trial (Teclistamab, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 6, 2022

Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • New York, New York
    Weill Cornell Medical College
Apr 10, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
Jan 6, 2023

Multiple Myeloma Trial in Italy, Switzerland (Nelfinavir, Lenalidomide, Dexamethasone)

Terminated
  • Multiple Myeloma
  • Milano, Italy
  • +10 more
Jul 4, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Multiple Myeloma Trial (Isatuximab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 19, 2022

Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)

Not yet recruiting
  • Follicular Lymphoma
  • Biospecimen Collection
  • +7 more
  • Duarte, California
  • +1 more
Oct 27, 2023

Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Teclistamab (Tec)
  • +4 more
  • Berlin, Germany
  • +8 more
Jan 19, 2023

MDS Trial in United States (Lenalidomide, Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Miami, Florida
  • +5 more
Sep 28, 2022

Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 11, 2022

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Multiple Myeloma Trial in Rochester (procedure, biological, drug)

Not yet recruiting
  • Multiple Myeloma
  • Biospecimen Collection
  • +12 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Sep 15, 2023

Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma Trial in Buffalo, Rochester (biological,

Active, not recruiting
  • Partial Response of Multiple Myeloma or Plasma Cell Leukemia
  • Plasma Cell Myeloma
  • Incomplete Freund's Adjuvant
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 12, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Peripheral T-Cell Lymphoma, Lenalidomide, CHOP Trial in Hangzhou (Lenalidomide, Cyclophosphamide, Doxorubicin)

Recruiting
  • Peripheral T-Cell Lymphoma
  • +2 more
  • Lenalidomide
  • +4 more
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022